Advertisement

Topics

Champions Oncology to collaborate with ALCMI to develop new cohort of PDX models

19:00 EDT 20 Aug 2017 | Pharmaceutical Technology

Champions Oncology has entered a collaboration with the Addario Lung Cancer Medical Institute (ALCMI) to develop a new cohort of PDX models in patients with ROS1 gene rearrangement.

Original Article: Champions Oncology to collaborate with ALCMI to develop new cohort of PDX models

NEXT ARTICLE

More From BioPortfolio on "Champions Oncology to collaborate with ALCMI to develop new cohort of PDX models"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...